Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company’s products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Metrics to compare | ANR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANRPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −5.1x | −0.6x | |
PEG Ratio | −0.63 | −0.18 | 0.00 | |
Price/Book | 3.6x | 3.7x | 2.6x | |
Price / LTM Sales | 2.0x | 12.5x | 3.3x | |
Upside (Analyst Target) | - | 315.5% | 39.1% | |
Fair Value Upside | Unlock | 5.7% | 5.4% | Unlock |